利伐沙班用于近期因急性感染性疾病住院患者的血栓预防:MAGELLAN研究的亚组分析
第35天时利伐沙班组静脉血栓栓塞症(VTE)发生率低于依诺肝素组(4.2% vs 6.6%,RR 0.64,95%CI 0.45-0.92),但主要安全结局事件增加(RR 2.42,95%CI 1.60-3.66)。
要点
- 第35天利伐沙班组VTE发生率4.2%,低于依诺肝素组的6.6%(RR 0.64,95%CI 0.45-0.92)。
- 肺部感染患者利伐沙班组VTE发生率第10天(RR 0.50,95%CI 0.28-0.90)和第35天(RR 0.54,95%CI 0.33-0.87)均较低。
- 利伐沙班组主要安全结局事件增加(RR 2.42,95%CI 1.60-3.66),疗效获益部分被出血结局抵消。
核心结论
- 延长的利伐沙班预防降低了因急性感染性疾病住院患者的VTE发生率,尤其是肺部感染患者,但疗效获益部分被出血结局抵消。
主要发现
- 第10天主要复合疗效结局在两种预防策略间无差异(利伐沙班组2.7% vs 依诺肝素组3.7%)。
- 第35天利伐沙班组VTE事件少于依诺肝素组(4.2% vs 6.6%)(相对危险度[RR] 0.64;95%置信区间[CI] 0.45-0.92)。
- 肺部感染患者中,利伐沙班组VTE发生率第10天(RR 0.50,95%CI 0.28-0.90)和第35天(RR 0.54,95%CI 0.33-0.87)均较低。
- 主要安全结局事件在利伐沙班组增加(RR 2.42,95%CI 1.60-3.66)。
关键数值与推荐
- 主要疗效结局为第10天和第35天无症状近端或症状性VTE的复合终点。
- 主要安全结局为主要或临床相关非主要出血的复合终点。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Essentials Net benefit of venous thromboprophylaxis (VTE) in patients hospitalized for infections is unknown. MAGELLAN trial subgroup analysis was performed for patients hospitalized for acute infectious diseases. At day 35, prolonged rivaroxaban prophylaxis reduced VTE compared to enoxaparin (4.2% vs. 6.6%). Rivaroxaban prophylaxis reduced VTE in patients hospitalized for active lung infections. SUMMARY: Background Despite the well-established association between infection and venous thromboembolism (VTE), there are few data specifically assessing the efficacy and safety of the VTE prophylaxis strategies for patients hospitalized for acute infectious diseases. Objectives To estimate the incidence of VTE and bleeding outcomes, comparing prolonged prophylaxis with rivaroxaban 10 mg daily for 35 days with enoxaparin 40 mg daily for 10 days. Patients/Methods A subgroup analysis of patients hospitalized for acute infectious diseases in the MAGELLAN trial was performed. The primary efficacy outcome was the composite of asymptomatic proximal or symptomatic VTE at days 10 and 35. The principal safety outcome was the composite of major or clinically relevant non-major bleeding. Results Three thousand one hundred and seventy-three patients with acute infectious diseases leading to hospitalization were randomized to either rivaroxaban (n = 1585) or enoxaparin/placebo (n = 1588), and received at least one dose of study medication. At day 10, primary composite efficacy outcomes did not differ between prophylaxis strategies (rivaroxaban, 2.7%; and enoxaparin, 3.7%). At day 35, there were fewer VTE events with rivaroxaban (4.2%) than with enoxaparin (6.6%) (relative risk [RR] 0.64; 95% confidence interval [CI] 0.45-0.92). Patients with pulmonary infections randomized to rivaroxaban had a lower incidence of VTE both at 10 days (RR 0.50, 95% CI 0.28-0.90) and at 35 days (RR 0.54, 95% CI 0.33-0.87). Primary safety outcome events were increased with rivaroxaban (RR 2.42, 95% CI 1.60-3.66). Conclusions Prolonged rivaroxaban prophylaxis reduced the incidence of VTE in patients hospitalized for acute infectious diseases, particularly those involving the lungs. Efficacy benefits were, in part, offset by bleeding outcomes. ClinicalTrials.gov Number: NCT 00571649.
引用
- Cohoon KP, De Sanctis Y, Haskell L, et al. Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study. J Thromb Haemost. 2018. PMID: 29753308. doi:10.1111/jth.14146
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。